Avacincaptad pegol sodium

• CAT Number: I043665
• CAS Number: 1491144-00-3
• Molecular Weight: 53500 (Approximately)
• Purity: 98%
• Target: C5
• Target Protein: P01031
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.

Avacincaptad pegol sodium（Cat No.:I043665）is a complement C5 inhibitor used for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). By specifically targeting and inhibiting the C5 protein in the complement cascade, it reduces inflammation and prevents the formation of membrane attack complexes, which contribute to retinal cell damage. Administered via intravitreal injection, Avacincaptad pegol slows the progression of GA, preserving vision in affected individuals. Its targeted mechanism offers a novel approach to managing AMD, addressing an unmet need in retinal disease therapy.

Reference

[1]. Jaffe GJ, Westby K, Csaky KG, et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021;128(4):576-586.
[Content Brief]

[2]. Patel SS, Lally DR, Hsu J, et al. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial [published online ahead of print, 2023 Mar 24]. Eye (Lond). 2023;10.1038/s41433-023-02497-w.
[Content Brief]

[3]. Powers, J. P., Dairaghi, D. J., & Jaen, J. C. (2011). Advances in the Discovery of C5a Receptor Antagonists. Annual Reports in Medicinal Chemistry, 171–186.